Pulling SEC filings + quote and writing the call…
Exousia Bio, Inc.
Next earnings ≈ Oct 14, 2026 · est. from filing cadence
Strong net margin (1370.5%); but revenue fell -67.4% YoY.
Revenue (FY2025) $3.75K · FY2025
Exousia Bio, Inc. shows $3.75K in FY2025 revenue (-67.4% YoY), a 1370.5% net margin.
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $0.00 | $11.5K | $3.75K |
| Gross profit | $0.00 | $1.83K | -$3.50K |
| Operating income | -$56.4K | — | — |
| Net income | -$56.4K | -$25.8K | $51.4K |
| Diluted EPS | $0.00 | $0.00 | $0.00 |
| Net margin | — | -224.4% | 1370.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0001939937, latest 10-Q filed 2026-06-16) · as of 6/22/2026, 9:51:38 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
1043 tracked peers · median